Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
6.60
-1.17 (-15.06%)
May 13, 2025, 4:00 PM - Market closed
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$238,551
Profits / Employee
-$785,551
Market Cap
4.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
JAGX News
- 5 days ago - Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Accesswire
- 6 days ago - Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts - Accesswire
- 13 days ago - Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients - Accesswire
- 14 days ago - REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Accesswire
- 15 days ago - Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast - Accesswire
- 26 days ago - Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress - Accesswire
- 4 weeks ago - Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting - Accesswire
- 5 weeks ago - Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - Accesswire